Equity, Bottom-up Analyst, Investics Research

Sameer Taneja

A buy-side analyst with over 15 years of experience investing in Asian markets and specializing in the mid-small cap space, emphasizing value investing in companies with good free cash flows/dividends and long-term holding horizons. 
Exempt Financial Adviser (EFA) under CrossASEAN Research Pte Ltd. It is important to note that the information provided by Investics Research is based on publicly available data and own knowledge, which has been gathered and analyzed from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions. All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include but are not limited to, company announcements, exchange filings, presentations, etc. Investics does not guarantee the accuracy and completeness of the forecasts, estimates, and/or other information.

Equity, Bottom-up Analyst

UMP Healthcare (722 HK): Deep Value Turnaround in FY25

UMP Healthcare (722 HK): Parsing the Announcement on The Major One-Time Gain

UMP Healthcare (722 HK) FY24 Results and Concall: 7x FY25PE,1.2x EV-EBITDA and 9% Dividend Yield

UMP Healthcare: An Undervalued Gem with a Promising Future in Hong Kong's Healthcare Market

Smartkarma Corporate Webinar | UMP Healthcare: An Undervalued Gem in Hong Kong’s Healthcare Market

UMP Healthcare Webinar Key Takeaways - Consolidation on the Investment Phase

Investics Research

It is important to note that the information provided by Investics Research is based on publicly available data and own knowledge, which has been gathered and analyzed from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions. All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include but are not limited to, company announcements, exchange filings, presentations, etc. Investics does not guarantee the accuracy and completeness of the forecasts, estimates, and/or other information.

Equity Bottom-up Research

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ump-healthcare-holdings-ltd" target="_blank" data-smartkarma-citation="entities:21005:1" rel="noopener">UMP Healthcare (722 HK)</a> reported FY23 profits down 26% YoY at 55 mn HKD, impacted by preoperating expenses and an impairment cumulatively of 40 mn HKD. </li>
<li>A slow Q4 FY23 didn't help either; revenues came in flat HoH instead of up 10% as our expectations and costs increased resulting in margin compression. </li>
<li>We believe the worst is behind us. The stock trades at 5.9x FY24 PE, with ~50% of the market cap in cash and an FY24 dividend yield of 8.5%.</li>
</ul>



UMP Healthcare (722 HK) reported FY23 profits down 26% YoY at 55 mn HKD, impacted by preoperating expenses and an impairment cumulatively of 40 mn HKD. 
A slow Q4 FY23 didn't help either; revenues came in flat HoH instead of up 10% as our expectations and costs increased resulting in margin compression. 
We believe the worst is behind us. The stock trades at 5.9x FY24 PE, with ~50% of the market cap in cash and an FY24 dividend yield of 8.5%.


UMP Healthcare 722 HK: Weak Q4 Lead to A Disappointing FY23, Worst Behind Us